Astellas Pharma Europe Ltd has announced that the EC has granted marketing authorisation for telavancin hydrochloride (Vibativ®), a once-daily injectable lipoglycopeptide antibiotic with a dual mechanism of action against gram-positive bacteria, including resistant pathogens such as MRSA. It is licensed for the treatment of adults with nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable. Telavancin